First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study
Por:
Provencio-pulla M, Ortega A, Coves J, Franco F, Marse R, Domine M, Guirado M, Carcereny E, Fernandez N, Martinez E, Blanco R, Leon L, Sanchez J, Sullivan I, Cobo M, Sanchez A, Massuti B
Publicada:
1 sep 2022
Resumen:
|